贝伐珠单抗注射液致药品不良反应的特点分析
Characteristics of Adverse Drug Reactions Induced by Bevacizumab Injection
何瑜娜 1王旖旎1
作者信息
- 1. 首都医科大学附属北京友谊医院全科医学科,北京 100050
- 折叠
摘要
目的:探讨贝伐珠单抗注射液致药品不良反应(ADR)的规律和特点,旨在为临床用药提供指导和帮助.方法:收集2017-2022 年该院使用贝伐珠单抗注射液的病例,共纳入符合入选标准的患者 161 例(男性患者 74 例,女性 87 例),调取其入院记录,回顾性分析发生ADR患者的性别、年龄、原患疾病以及ADR严重程度分级.结果:161 例使用贝伐珠单抗注射液的患者中,57 例患者发生贝伐珠单抗注射液药品说明书及相关文献中提及的ADR 92 例次.在排除患者基础疾病、联合用药、统计不合理等相关因素的基础上,认为其ADR的发生与使用贝伐珠单抗注射液高度相关的患者共 42 例(76 例次).大部分ADR在可控范围内,给予干预后患者可继续使用该药.高度怀疑与贝伐珠单抗注射液相关的 ADR主要涉及血液系统损害(42 例,发生率为26.1%)、胃肠道反应(16 例,发生率为 9.9%)、循环系统损害(18 例,发生率为 11.2%)、泌尿系统损害(蛋白尿 3 例,发生率为1.9%)、皮肤及其附件损害(6 例,发生率为 3.7%)等;其中出血 9 例(发生率为 5.6%),高血压 6 例(发生率为 3.7%),血栓 3 例(发生率为 1.9%).结论:贝伐珠单抗注射液所致ADR可涉及多个器官和(或)系统.临床使用时,应熟悉贝伐珠单抗注射液的ADR特点,有相关系统基础病或使用该药可能发生严重ADR的高危人群应谨慎使用该药;在使用该药物过程中,需要对患者出现的异常指标及不适情况密切监测,及时规范处理,防范严重ADR的发生.
Abstract
OBJECTIVE:To probe into the rules and characteristics of adverse drug reactions(ADR)induced by bevacizumab injection,so as to provide guidance and assistance for clinical medication.METHODS:A total of 161 patients(74 males and 87 females)received bevacizumab injection in the hospital from 2017 to 2022 who met the inclusion criteria were enrolled,and the admission records were retrieved to retrospectively analyse the gender,age,primary disease and ADR severity grading of the patients who developed ADR.RESULTS:Among the 161 patients received bevacizumab injection,57 patients had developed 92 cases of ADR that mentioned in the drug instructions and related literature of bevacizumab injection.Based on the exclusion of patients'underlying diseases,drug combination,statistical irrationality and other related factors,a total of 42 patients(76 cases)were considered to have a high correlation between the occurrence of ADR and the application of bevacizumab injection.Most ADR were within the controllable range and the patients could continue to use the drug after intervention.ADR that highly suspected to be associated with bevacizumab injection were mainly related to hematological system damage(42 cases,the incidence rate was 26.1%),gastrointestinal reactions(16 cases,the incidence rate was 9.9%),circulatory system damage(18 cases,the incidence rate was 11.2%),urinary system damage(3 cases of proteinuria,the incidence rate was 1.9%)and damage of skin and its accessories(6 cases,the incidence rate was 3.7%).Among them,there were 9 cases of bleeding(the incidence rate was 5.6%),6 cases of hypertension(the incidence rate was 3.7%)and 3 cases of thrombosis(the incidence rate was 1.9%).CONCLUSIONS:ADR induced by bevacizumab injection can involve multiple organs and(or)systems.Clinical application should be familiar with the ADR characteristics of bevacizumab injection,and bevacizumab injection should be used with caution in high-risk groups with relevant systemic underlying diseases or those may develop severe ADR.During the application of bevacizumab injection,it is necessary to closely monitor the abnormal indicators and discomforts in patients,and regulate the treatment in time to prevent the occurrence of severe ADR.
关键词
贝伐珠单抗/药品不良反应/回顾性研究Key words
Bevacizumab/Adverse drug reactions/Retrospective study引用本文复制引用
出版年
2024
国家科技期刊平台
NSTL
万方数据